Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort.

HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatology international Tanaka, Y. n., Ogawa, E. n., Huang, C. F., Toyoda, H. n., Jun, D. W., Tseng, C. H., Hsu, Y. C., Enomoto, M. n., Takahashi, H. n., Furusyo, N. n., Yeh, M. L., Iio, E. n., Yasuda, S. n., Lam, C. P., Lee, D. H., Haga, H. n., Yoon, E. L., Ahn, S. B., Wong, G. n., Nakamuta, M. n., Nomura, H. n., Tsai, P. C., Jung, J. H., Song, D. S., Dang, H. n., Maeda, M. n., Henry, L. n., Cheung, R. n., Yuen, M. F., Ueno, Y. n., Eguchi, Y. n., Tamori, A. n., Yu, M. L., Hayashi, J. n., Nguyen, M. H. 2020

Abstract

Despite HCV cure, patients remain at risk for HCC, but risk factor data for HCC following SVR are limited for Asian patients.To address this gap, we analyzed 5814 patients (5646 SVR, 168 non-SVR) from the Real-World Evidence from the Asia Liver Consortium for HCV (REAL-C) who did not have HCC or a history of HCC at baseline (pre-DAA treatment) and did not develop HCC within 6 months of baseline. To assess the effect of SVR on HCC incidence, we used 1:4 propensity score matching [(PSM), age, sex, baseline cirrhosis, and baseline AFP] to balance the SVR and non-SVR groups.In the PSM cohort (160 non-SVR and 612 SVR), the HCC incidence rate per 100 person years was higher in the non-SVR compared to the SVR group (5.26 vs. 1.94, p?

View details for DOI 10.1007/s12072-020-10105-2

View details for PubMedID 33277685